Enrolling a global clinical trial is hard. Completing enrollment early is harder. Amgen accomplished both during a global pandemic.
Like many sponsors, Amgen was faced with the challenge of enrolling a global study in the middle of a COVID-19 pandemic that had decreased patient enrollment in trials across the world. Through proactive planning and rapid decision-making, Amgen was on track to meet their original protocol-defined enrollment target ahead of their planned Last Subject Enrolled date.
In this webinar, you’ll learn how Amgen’s trial teams deployed a strategy centered on site-focused collaboration and technology-enabled insights to respond rapidly to enrollment trends and enroll patients more quickly than originally projected.
Riddhi has 14 years of experience in Clinical Development. She joined Amgen in 2011 as a Senior Associate within Global Study Management, she was promoted to Global Clinical Trial Manager (GCTM) in 2012 and further to Clinical Program Management - Senior Manager (CPM-SM) in 2019. Riddhi has worked on various products and studies across Phase 1-4. Prior to joining Amgen Riddhi held positions of increasing responsibility at Chiltern, culminating at Senior CRA. Riddhi earned a Bachelor's of Science Biochemistry degree from the University of Surrey.
Ralph Passarella is the CEO and Co-Founder of Reify Health, where he and his team are working to accelerate the development of new, life-saving therapies. Through their work at Reify, Ralph and team also co-founded Signal Vine, an education technology company helping students navigate the administrative parts of higher education. Ralph currently serves on the Signal Vine Board of Directors.
Prior to starting Reify Health, Ralph graduated from Vanderbilt University with a BA in Molecular and Cellular Biology and completed the first two years of the MD/PhD program at Johns Hopkins University School of Medicine.
Before putting his studies on pause, Ralph’s work as an entrepreneur and researcher was recognized nationally by the National Cancer Institute, the American Medical Informatics Association, the American Association for Cancer Research, and the Clinical Global Initiative.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.